evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

139 questions · 147 findings · 16 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 21 · 14.3%GRADE not reported 4 · 2.7%Very low 26 · 17.7%Low 61 · 41.5%Moderate 29 · 19.7%High 6 · 4.1%

Systemic corticosteroids vs placebo or control

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Cerebral palsy · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Death or cerebral palsy · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Perineural vs intravenous dexamethasone

Incidence of serious adverse events (we used the NIH definition of adverse events. A serious event includes death, a life‐threatening event that requires hospitalization or prolonged hospitalization, disability or congenital anomaly) · peripheral nerve block

The review found no eligible studies for this question.

1 finding from 1 review

Perineural vs intravenous dexamethasone

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · peripheral nerve block
3 findings from 1 review

Lower vs higher cumulative dose dexamethasone regimen

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).

1 finding from 1 review

Individual tailored vs continuous tapered dexamethasone regimen

Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia

Individual tailored showed no clear difference in death or cerebral palsy at 1 to 3 years compared with continuous tapered dexamethasone regimen (moderate certainty).

1 finding from 1 review